Taltz has the best access in the IL-17A antagonist class in psoriasis*
*Based on the number of covered lives across commercial and Part D plans

Learn more
Taltz brand logo header


Consider Taltz as your first-line biologic for patients like Taylor*

Hypothetical Patient


has moderate to severe plaque psoriasis

  • He is struggling with his psoriasis, even in challenging body areas like scalp or nail psoriasis
  • He needs rapid relief for today and durable results for tomorrow because every day is special

Each day of Taylor's life is full of special moments

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.


Patient Manifestations to Consider When Choosing Taltz for Moderate-to-Severe Plaque Psoriasis

Disease state and patient expectations

Prevalence of psoriatic disease

About 125M people worldwide have psoriasis1

About 30% of people with plaque psoriasis also have psoriatic arthritis2

Approximately 50% of people with plaque psoriasis experience a flare-up on their scalp3

Approximately 50% of people with plaque psoriasis have nail involvement4

Up to 63% of people with plaque psoriasis have or have had genital psoriasis5

Up to 17% of people with plaque psoriasis have palmoplantar psoriasis6


Patients want clearance that lasts, with a rapid response that matters7

Percentage of patients indicating high importance for each attribute*

Want high probability of achieving clear skin

Want to keep skin clear for 2 to 3 years

Want rapid response

Want effectiveness in nail, scalp, genitals, palms, and soles

*Patients rated each attribute from 1 (not important) to 10 (highest importance). High importance was defined as a response of 7-10.

Patients expect
50% clearer skin in about

16 days

on average

Patients expect
completely clear skin in about

34 days

on average


The survey consisted of 500 adult US PsO patients with self-assessed moderate to severe disease (BSA ≥3%) and current or previous use of systemic therapy (biologic and non-biologic) within the past 12 months who were unsatisfied with their current treatment. All data presented are descriptive with frequencies and means.

In the survey, patients responded to the following question: Approximately how many days would you expect a systemic psoriasis treatment to take in order to deliver each of the following for you?

PsO=plaque psoriasis; BSA=body surface area.

References: 1. Psoriasis statistics. National Psoriasis Foundation. Accessed September 17, 2021. https://www.psoriasis.org/psoriasis-statistics/ 2. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729-735. 3. 10 reasons your scalp itches and how to get relief. American Academy of Dermatology Association. Accessed September 17, 2021. https://www.aad.org/public/everyday-care/itchy-skin/itch-relief/relieve-scalp-itch 4. Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(suppl 1):1-5. 5. Ryan C, Menter A, Guenther L, et al; IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179:844-852. 6. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686-1692. 7. Data on file. Lilly USA, LLC. DOF-IX-US-0169.



Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.


Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Serious hypersensitivity reactions, including angioedema and urticaria (each ≤ 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post­-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Prior to initiating therapy with Taltz, consider completion of all age­-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.


Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please see Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.



Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.